What is Cell Microsystems?
Cell Microsystems specializes in the development of sophisticated instrumentation designed for the precise imaging, sorting, and isolation of individual cells and colonies. Its flagship technology, the CellRaft AIR System, has become a cornerstone for research initiatives spanning CRISPR gene editing, oncology, and stem cell biology. By providing automated solutions for 3D cell culture and clonal outgrowth, the company addresses the critical need for high-fidelity data in complex biological workflows.
The firm serves a diverse ecosystem of research institutions and pharmaceutical enterprises, enabling them to streamline their experimental processes. Through its commitment to innovation in cellular analysis, Cell Microsystems has established itself as a vital partner for organizations seeking to push the boundaries of genetic and therapeutic discovery.
How much funding has Cell Microsystems raised?
Cell Microsystems has raised a total of $14.6M across 4 funding rounds:
Grant
$1.5M
Debt
$150K
Debt
$292K
Other Financing Round
$12.7M
Grant (2018): $1.5M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Debt (2021): $292K supported by PPP
Other Financing Round (2021): $12.7M featuring Telegraph Hill Partners
Key Investors in Cell Microsystems
Telegraph Hill Partners
Telegraph Hill Partners is a San Francisco-based private equity firm that focuses on providing growth capital to commercial-stage companies within the life science, medical technology, and healthcare sectors.
PPP
Public-Private Partnership
Undisclosed Grant Provider
An institutional entity providing non-dilutive grant funding to support scientific research and technological development.
What's next for Cell Microsystems?
With the recent infusion of capital, Cell Microsystems is poised to deepen its market penetration and enhance its technological infrastructure. The strategic focus will likely shift toward scaling manufacturing capabilities to meet the rising demand for its automated cell counting and isolation systems. Furthermore, the company is expected to leverage this financial backing to explore new applications for its technology in emerging fields such as personalized medicine and advanced therapeutic development.
As the company continues to refine its product suite, the emphasis will remain on maintaining its competitive edge through continuous innovation. By aligning its growth trajectory with the evolving needs of the biotech industry, Cell Microsystems is set to solidify its position as a leader in the high-throughput cellular analysis market.
